<DOC>
	<DOCNO>NCT00777738</DOCNO>
	<brief_summary>This trial design evaluate efficacy toxicity Bortezomib , inhibitor proteasome use multiple myeloma , patient advance Waldenström 's Macroglobulinemia disease .</brief_summary>
	<brief_title>Efficacy Bortezomib ( Velcade ( R ) ) Patients With Advanced Waldenström Macroglobulinemia</brief_title>
	<detailed_description>Open , prospective , multicenter , non control phase IIA trial Primary objectives Evaluation efficacy safety Velcade monotherapy patient advanced stage Waldenström Macroglobulinemia . Secondary objective Evaluation activity association High Dose Dexamethasone ( HD DXM ) Velcade patient resistant Velcade Alone For patient - Overall survival - Safety - Quality life - Duration response sample size : With type I error alpha 5 % type II error beta 20 % two-sided test , number patient need study 34 Number center : 28 Centers participate French cooperative group CLL/WM</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>● Established diagnosis Waldenström macroglobulinemia ( 2nd Workshop Waldenstrom 's macroglobulinemia ) Patient must 1 ( 2 ) line chemotherapy contain alkylating agent and/or Fludarabine : /or monoclonal antibody must : Life expectancy &gt; 3 month Age &gt; 18 year ECOG performance status 012 ANC &gt; 1 x 109/L Creatinine clearance , calculate accord formula cockcroft Gault &gt; 40 ml/min Total bilirubin &lt; 2x ULN ASAT , ALAT &lt; 2x ULN A negative serum pregnancy test one week prior treatment must available premenopausal woman woman &lt; 2 year onset menopause Adequate contraceptive method male premenopausal females 6 month treatment discontinuation . Written inform consent Platelets &gt; 100X 109 Active secondary malignancy chemotherapy/radiotherapy neoplastic disease Waldenström macroglobulinemia prior study Medical condition require longterm ( estimate one month ) use oral corticosteroid Patients active bacterial , viral fungal infection Known infection HIV , Hepatitis B ( except post vaccinal profile ) C Treatment , investigational agent participate another trial within 30 day prior enter study Lactation/pregnancy Concurrent severe disease exclude administration therapy heart insufficiency NYHA grade III/IV , LEVF &lt; 50 % RF &lt; 30 % , myocardial infarction within past 6 month prior study Severe pulmonary heart problem ( acute diffuse pulmonary pericardial disease ) Severe chronic obstructive lung disease hypoxemia Severe diabetes mellitus Hypertension difficult control Impaired renal function creatinine clearance &lt; 40 ml/min accord formula Cockcroft Gault Cerebral dysfunction Richter 's syndrome Neuropathy &gt; grade 1 Positive Beta HCG Severe Hepato cellular alteration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Advanced Waldenström 's macroglobulinemia</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>